Skip to main content

Percutaneous Management of Mitral Valve Disease

  • Chapter
  • First Online:
  • 511 Accesses

Abstract

Almost all cases of mitral stenosis are due to cardiac disease secondary to rheumatic fever and consequent rheumatic heart disease. Uncommon causes of mitral stenosis include calcification of the mitral valve leaflets and congenital heart disease including a parachute mitral valve. The natural history of rheumatic mitral stenosis is of an asymptomatic latent phase following the initial episode of rheumatic fever. This latent period lasts an average of 16 ± 5 years. Progressive and gradual commissural fusion eventually causes the characteristic symptoms and progression to severe disability may take 9 ± 4 years. Precipitous clinical presentation may occur at the onset of atrial fibrillation causing tachycardia or thromboembolic stroke.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Recommended Reading

  1. Abascal VM, Wilkins GT, O’Shea JP et al. Prediction of successful outcome in 130 patients undergoing percutaneous balloon mitral valvotomy. Circulation. 1990;82(2):448–56.

    Article  CAS  PubMed  Google Scholar 

  2. Feldman T, Wasserman HS, Herrmann HC et al. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol. 2005;46:2134–40.

    Article  PubMed  Google Scholar 

  3. Maisano F, Franzen O, Baldus S et al. Percutaenous mitral valve interventions in the real world: early and one-year results from the ACCESS-EU, a prospective, multicenter non-randomised post-approval study of the Mitraclip therapy in Europe. J Am Coll Cardiol. 2013;62(12):1052–61.

    Article  PubMed  Google Scholar 

  4. Nobuyoshi M, Arita T, Shirai S, Hamasaki N, Yokoi H, Iwabuchi M, Yasumoto H, Nosaka H. Percutaneous balloon mitral valvuloplasty – a review. Circulation. 2009;119:e211–9.

    Article  PubMed  Google Scholar 

  5. Wan B, Rahnavardi M, Tian DH, Phan K, Munkholm-Larsen S, Bannon PG, Yan TD. A meta-analysis of Mitraclip system versus surgery for treatment of severe mitral regurgitation. Ann Cardiothorac Surg. 2013;2(6):683–92.

    PubMed  PubMed Central  Google Scholar 

  6. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Heart. 1988;60(4):299–308.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anitha Varghese MD, MRCP .

Editor information

Editors and Affiliations

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Pre-procedural TOE. Mitral valve anatomical assessment showed both mitral valve leaflets are thickened; anterior mitral valve leaflet 4 mm, posterior mitral valve leaflet 3.3 mm (Wilkins 2). There is restricted motion of valve leaflet base with bowing in diastole (Wilkins 3). The chordae are shortened and thickened (Wilkins 2), with focal calcification of the anterolateral commissure (Wilkins 2). Total Wilkins score = 9. The left atrium is dilated and demonstrates the phenomenon of spontaneous echo contrast due to slow blood flow. (AVI 852 kb)

Pre-procedural TOE. Mitral valve anatomical assessment showed both mitral valve leaflets are thickened; anterior mitral valve leaflet 4 mm, posterior mitral valve leaflet 3.3 mm (Wilkins 2). There is restricted motion of valve leaflet base with bowing in diastole (Wilkins 3). The chordae are shortened and thickened (Wilkins 2), with focal calcification of the anterolateral commissure (Wilkins 2). Total Wilkins score = 9. The left atrium is dilated and demonstrates the phenomenon of spontaneous echo contrast due to slow blood flow. (AVI 535 kb)

Pre-procedural TOE. Unfortunately there was evidence of thrombus in her left atrial appendage. Risk of peri-procedural thromboembolic stroke would have been increased and therefore planned PBMV was deferred to allow intensification of antithrombotic medication by increasing target INR and later, because of persistent thrombus, by addition of low dose aspirin. When the thrombus has resolved, PBMV was performed. (AVI 465 kb)

Mitral valve planimetry of orifice area using three-dimensional (3 D) TOE. (AVI 792 kb)

Valvuloplasty procedure. Set-up left ventriculogram to delineate position of mitral valve apparatus. (AVI 2873 kb)

Valvuloplasty procedure. Correct orientation for transseptal access is confirmed by tenting of the inter-atrial septum immediately prior to puncture. (AVI 460 kb)

Valvuloplasty procedure. The Inoue balloon is sized according to the patient’s height. The deflated Inoue balloon is manipulated across the stenosed mitral valve, and the tip is moved to the ventricular apex to ensure no entanglement within the chordae tendinae. Subsequently, the balloon is inflated. At first, the distal portion opens and the balloon is pulled back into position at the mitral orifice. Following further dilatation, the proximal part opens, and finally the waist, which performs the commissurotomy. Sequential and progressively larger dilatations were performed. The initial inflation was at 22 mm, then 24 mm and finally 26 mm, with assessment of the result after each inflation. (AVI 8444 kb)

Valvuloplasty procedure. Live 3D TOE of the final 26 mm balloon dilatation. The deflated balloon can be seen exploring the mitral valve until the opening is found and it is then advanced into the LV. Later the atrial portion of the balloon can be seen filling. (AVI 6610 kb)

Valvuloplasty procedure. Invasive haemodynamic and non-invasive TOE measurements confirmed good relief of stenosis with the transmitral gradient falling from 11 mmHg to 7 mmHg and the mitral valve area increasing to 1.3 cm2. There was no significant post-procedural mitral regurgitation. (AVI 681 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag London

About this chapter

Cite this chapter

Varghese, A., Uren, N., Ludman, P.F. (2017). Percutaneous Management of Mitral Valve Disease. In: Varghese, A., Uren, N., Ludman, P. (eds) Cases in Structural Cardiac Intervention. Springer, London. https://doi.org/10.1007/978-1-4471-4981-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4981-1_4

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4980-4

  • Online ISBN: 978-1-4471-4981-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics